Among early HCC cases (BCLC stage 0 and A), we found that 36.0% (9/25) of patients had elevated AFP levels, while 80.0% (20/25) of patients had high miR-19-3p expression. The gene discussed is AFP; the disease is hepatocellular carcinoma.